Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057250 · ClinicalTrials.gov registry record · Phase 3
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
NCT02057250 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 217 participants.
The verdict
NCT02057250, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
Study Summary
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants. Secondary Objective: To compare the pharmacokinetic (PK) exposure of sarilumab administered by AID versus prefilled syringes (PFS).
Interventions
- DRUG Methotrexate
- DRUG Sarilumab
- DRUG Sulfasalazine
- DEVICE Auto-Injector Device (AID)
- DEVICE Pre-filled Syringe (PFS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057250
The ClinicalTrials.gov registry entry for NCT02057250 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methotrexate is the first listed.
NCT02057250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057250 about?
NCT02057250 is a clinical study titled "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis". Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants. Secondary Objective: To compare the pharmacokinetic (PK) exposure of sarilumab administered by AID versus prefilled syringes (PFS).
What is the current status of trial NCT02057250?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2014-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02057250?
The interventions under investigation include: Methotrexate (DRUG), Sarilumab (DRUG), Sulfasalazine (DRUG), Auto-Injector Device (AID) (DEVICE), Pre-filled Syringe (PFS) (DEVICE).
Who is sponsoring clinical trial NCT02057250?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.